



Marker for Neuropsychiatric Disorders

There is a critical need for quick, accurate diagnoses of autism, schizophrenia, depression, bipolar disorders and other neuropsychiatric disorders. Mental and behavioral disorders affect more than 25% of all people at some time during their lives.

Current diagnosis is based on symptomatic characteristics. However, this is difficult especially if the patient is borderline. A quick, accurate diagnosis is critical for early intervention and/or better control through medical treatment.

A blood diagnostic test has been developed based on the presence of Reelin in peripheral blood. Reelin is a secretory glycoprotein responsible for normal lamination of brain and has recently been implicated in the pathology of schizophrenia, bipolar disorder, major depression, a variant of lissencephaly and autism.

Significant and specific alterations in blood Reelin levels occur in schizophrenic, autistic, depressed and bipolar patients.

Features & Benefits

- Tests for neuropsychiatric conditions that are not currently diagnosable with blood or genetic tests
- Improves patient care and outcome through early diagnosis and monitoring
- Early diagnostic test for Autism-patent allowed

Technology Status

Proof of concept established. Additional validation and mechanistic studies underway.

IP Status

US Patent 7,341,844; additional pending applications.

Primary Inventor

S. Hossein Fatemi, MD, PhD
Department of Psychiatry

Questions? Contact:

Sue Patow,
Technology Marketing Manager

Ph 612.624.3966
E-mail patow001@umn.edu

UM Docket Z02081

Learn about more groundbreaking discoveries at www.research.umn.edu/techcomm

